Ian D. Hickson

发表

USP45 deubiquitylase controls ERCC1–XPF endonuclease-mediated DNA damage responses

D. Alessi, J. Rouse, Thomas Macartney, 2014, The EMBO journal.

Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.

N. Curtin, I. Hardcastle, R. Griffin, 2007, Journal of medicinal chemistry.

Ubiquitinated aldolase B accumulates during starvation‐induced lysosomal proteolysis

Ian D. Hickson, W. Dunn, S. Lenk, 1999, Journal of cellular physiology.

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers

David M. Wilson, A. Jadhav, E. Rakha, 2021, Cancers.

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Lisa L. Smith, C. Chresta, S. Guichard, 2010, Cancer research.

Role of Topoisomerase II α and β Isozymes in Determining Drug Resistance in vitro and in vivo

A. Harris, M. Sandri, Ian D. Hickson, 1995 .

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Yolanda T. Chong, T. Bush, G. Bignan, 2021, Molecular Cancer Therapeutics.

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

N. Curtin, S. Jackson, P. Reaper, 2004, Cancer Research.

O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow.

J. Ashby, G. Margison, T. Dexter, 1997, Blood.

- Benzylguanine Potentiates the In Vivo Toxicity and Clastogenicity of Temozolomide and BCNU in Mouse Bone Marrow

J. Ashby, G. Margison, T. Dexter, 1997 .

Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers

E. Rakha, N. Mongan, R. Ali, 2022, npj Precision Oncology.

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).

Yolanda T. Chong, T. Bush, G. Bignan, 2021, Journal of medicinal chemistry.

Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

Adrian L Harris, A. Harris, A. Boddy, 2005, Clinical Cancer Research.

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

M. Noble, J. Endicott, M. Waring, 2021, Journal of medicinal chemistry.

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.

Charles Y. Lin, S. Knapp, T. Westbrook, 2020, Cell chemical biology.

The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.

A. Harris, I. Hickson, H. Turley, 1997, British Journal of Cancer.

319 POSTER Pharmacodynamics and anti-tumour activity of KU-0063794, a potent and specific inhibitor of mTOR kinase

C. Chresta, B. Davies, Ian D. Hickson, 2008 .

Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.

A. Harris, C. Chresta, J. Masters, 1991, Cancer research.

Isolation and partial characterisation of a mammalian cell mutant hypersensitive to topoisomerase II inhibitors and X-rays.

Ian D. Hickson, S. Davies, S. Davies, 1990, Mutation research.

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

A. Harris, H. Turley, D. Hochhauser, 1996, British Journal of Cancer.

Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.

A. Harris, D. Sheer, J. Jenkins, 1992, Nucleic acids research.

Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions.

A. Harris, P. Workman, M. Walton, 1990, Cancer research.